1 minute read | June.18.2026
ABIONYX Pharma, a next-generation biopharmaceutical company, has completed a €32.7 million financing transaction comprising a capital increase with preferential subscription rights of approximately €18.7 million and a bond financing for a total amount of €14 million.
Orrick advised ABIONYX Pharma on the structuring and implementation of this transaction.
ABIONYX Pharma is a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through breakthrough biotherapies that address life-threatening conditions with no effective treatments. Leveraging its proprietary apoA-I–based technology platform, ABIONYX Pharma develops innovative biologics and HDL-derived vectors that target the immune and inflammatory dysregulation underlying sepsis and other severe diseases.
The financing will support the advancement of ABIONYX Pharma’s clinical and regulatory agenda, enabling the company to progress its pipeline of innovative therapies addressing critical unmet medical needs in sepsis and intensive care — areas where effective treatments remain scarce.
The Orrick team was led by Vianney Toulouse (Partner), assisted by Mathilde Duchamp and Léa Boutin from the M&A/Capital Markets team dedicated to Life Sciences, under the supervision of Alain Decombe (Senior Partner).